Search PubMed⌕ Search

Biomedical subjects

M Schachter

Publications and source records attributed to M Schachter.

267 records · Page 15Linked to original sources
PubMedDate not supplied

Method for control of patient flow.

This article describes a method of patient flow control currently being used in the radiology department of Grant Hospital of Chicago. The control board specifically designed for this department's needs enables personnel to follow visually a patient's progress through the department in logical sequence. Its effectiveness enhances the quality of patient care.

Appointments and Schedules↗
PubMedDate not supplied

[The Rorschach test in the diagnosis of Pierre-Maries so-called subjective craniotraumatic syndrome, or traumatogenic minimal brain syndrome].

A relatively poor bibliography is devoted to the Rorschach-Test diagnosis of the cranio-traumatic subjective syndrome of Pierre-Marie, or, in our own formulation, syndrome of minimal traumatogenic cerebral injury. Following a short review concerning this syndrome and the literature mentioning the Rorschach-test, we relate our own experience based on 58 cases of Pierre-Marie syndrome and 61 cases of neuro-organic not-traumatic diseases, compared with 60 neurologically normal cases, submitted to this test. Two comparative tables allow the following conclusions: a) the Rorschach-test of a Pierre-Marie syndrome is clearly distinct from that of a neurologically normal subject; b) this test is largely near to that who is given by not-traumatic neuro-organic diseases and, c) there are no a specific Ro-profile of the Pierre-Marie syndrome. Confirmation, with additional facts, concerning the characteristics of the Ro-test of these patients.

Adult↗
PubMedDate not supplied

Centrally acting antihypertensives: not obsolete after all.

Centrally acting antihypertensive drugs, or sympatholytics, have a long history of efficacy, including some of the earliest major clinical trials, but they are now little used in the UK and elsewhere. This has been due to the introduction of new drugs with better tolerability than the centrally acting agents. In the case of clonidine there was also concern about rebound hypertension. However, at least some hypertensives may benefit from a centrally acting drug and a new class of agents, the imidazoline agonists, has recently been developed. One of these, moxonidine, is available in the UK. Clinical studies so far suggest that its efficacy is comparable to currently used drugs and that adverse effects are less severe than with earlier sympatholytics. Rebound hypertension has not been described, so this may lead to a revival in interest in these drugs as antihypertensive agents.

Adult↗